ストックスクリーナーアプリを入手
3.51
3.31%
-0.12
Nasus Pharma Ltd. (NSRX) 最新ニュース
At the October 8 meeting, Nasus Pharma (NSRX) shareholders approved all agenda items except one. - Stock Titan
Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com South Africa
Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com
Nasus Pharma enrolls first patient in NS003 phase 1 trial - Investing.com
Nasus Pharma Enrolls First Patient in Phase 1 PK Trial of NS003 Intranasal Ondansetron for CINV and PONV - Quiver Quantitative
Nasus Pharma Announces Enrollment and Dosing of First - GlobeNewswire
Nasus Pharma CFO Eyal Rubin Resigns, Files Ownership Disclosure - kalkinemedia.com
Rubin Eyal ceases as CFO at Nasus Pharma (NSRX) - Stock Titan
New Nasus Pharma (NYSE: NSRX) share plan could dilute holders while funding anaphylaxis drug trials - Stock Titan
Nasus Pharma (NSRX) taps BTIG to sell new shares for drug trials - Stock Titan
FDA clears nasal epinephrine study for Nasus Pharma (NSRX) targeting anaphylaxis - Stock Titan
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis - GlobeNewswire
Nasus Pharma Ltd SEC Filing (Sep 14, 2026) - Stock Titan
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis - Yahoo Finance
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Nasus Pharma to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative
A company developing nasal allergy medicine will present in New York - Stock Titan
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
A $750,000 sale bonus? Nasus Pharma (NSRX) puts CEO pay to a shareholder vote - Stock Titan
Nasus Pharma (NYSE: NSRX) sets $50M share shelf for working capital and drug development - Stock Titan
Nasus Pharma Announces Transition of Chief Financial Officer - Yahoo Finance
Nasus Pharma (NSRX) CFO exit ushers in long-time insider as interim - Stock Titan
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update - GlobeNewswire
Nasus Pharma Appoints Pharmaceutical Industry Veteran - GlobeNewswire
Nasus Pharma (NYSE American: NSRX) taps Brendan O’Grady to lead next phase - Stock Titan
A new CEO takes charge as Nasus Pharma advances nasal anaphylaxis treatment - Stock Titan
NSRX Forecast — Price Target — Prediction for 2027 - TradingView
Nasus Pharma Announces Positive Results from Preclinical - GlobeNewswire
NSRX - Finviz
Nasus Pharma to Participate in Upcoming Investor Conferences - Yahoo Finance
NSRX: Nasus Pharma Ltd. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Nasus Pharma Advances NS002 Towards Pivotal Study Following - GlobeNewswire
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update - Yahoo Finance
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold - GlobeNewswire
Nasus Pharma to Present Topline Analysis from NS002 - GlobeNewswire
Nasus Pharma Announces Pricing of $15.0 Million Private Placement - GlobeNewswire
6.05%
1.35%
大文字化:
|
ボリューム (24 時間):